Compare Docusign Inc (DOCU) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs Nuwellis Inc — how do they compare? Docusign Inc trades at $71.13 (market cap $13.35B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Docusign Inc is far larger — about 6068.2× Nuwellis Inc's market cap, and Docusign Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and Nuwellis Inc for 26 Days on average.
| DOCU | NUWE | |
|---|---|---|
Market Cap | $13.35B | $2.20M |
Volume | 3,158,858 | 121,544 |
Sector | Technology | Health |
52-Week High | $73.14 | $146.65 |
52-Week Low | $41.75 | $0.68 |
Typical Hold Time | 71 Days | 26 Days |
Enterprise Value | $12.76B | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $71.08, up 3.16% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is solid, and profitability metrics like net income margin and ROE show significant improvement. Recent news highlights AI integration in contract processing and leadership in workflow software, though insider selling has been noted.
The outlook for DOCU is positive, driven by earnings beats and AI adoption, but risks include valuation concerns with a P/E of 43.55 and insider selling. The consensus price target of $68.75 suggests limited upside from current levels, indicating a cautious stance from analysts despite bullish technical signals.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
